SEC Tracker
Get the app

ArriVent BioPharma AVBP

ArriVent BioPharma misses trial goal

Form
8-K
Filed
Importance
Routine
  1. Phase 3 FURVENT trial did not meet PFS primary endpoint
  2. 240mg firmonertinib showed 11.0 months PFS vs 9.5 months control
  3. Safety profile consistent with prior studies
  4. No new safety signals identified

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when ArriVent BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. uniQure QURE public float $765M, Jun 30, 2025
  3. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  4. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  5. Immunome IMNM public float $729M, Jun 30, 2025